-
Case Report
-
J Mult Scler Neuroimmunol. 2022;13(2):30-34. Published online December 31, 2022.
- 리툭시맙 치료로 호전된 재발 중추신경계원발혈관염 1예
-
김태영, 김용진, 김민, 전재현, 박현미, 신동훈, 양지원
-
가천대학교 의과대학 길병원 신경과
-
- Favorable Response to Rituximab in a Patient with Recurrent Primary Angiitis of the Central Nervous System: A Case Report and Literature Review
-
Tae Young Kim, Yong Jin Kim, Min Kim, Jae Hyun Jeon, Hyun-Mi Park, Dong Hoon Shin, Jiwon Yang
-
Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
-
- Corresponding author: Jiwon Yang Tel: +82-32-460-3346, Fax: +82-32-460-3344, Email: nryang@gilhospital.com
- Received: November 4, 2022; Revised: November 24, 2022 Accepted: November 25, 2022.
- Abstract
- Primary angiitis of the central nervous system (PACNS) is an uncommon disorder restricted to the brain and spinal cord and leading to inflammation and destruction of vessels without evidence of vasculitis outside the central nervous system. Current treatments of PACNS are based on extrapolation from other forms of systemic vasculitis and retrospective assessments because there are no prospective studies of therapeutic strategies. We report a case of recurrent PACNS that showed a successful response to rituximab treatment.Journal of Multiple Sclerosis and Neuroimmunology 13(2):30-34, 2022
Keywords :Central nervous system angiitis; Rituximab; Recurrence
